Durability of SARS-CoV-2 Specific IgG Antibody Responses Following Two Doses of Match and Mixed COVID-19 Vaccines Regimens in Saudi Population

References

• WHO. Coronavirus disease (COVID-19) pandemic. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019. Accessed March 21, 2022.
   Google Scholar
• Randad PR, Pisanic N, Kruczynski K, et al. COVID-19 serology at population scale: SARS-CoV-2-specific antibody responses in saliva. J Clin Microbiol. 2021;59(1):24–0112300.
   Web of Science ®Google Scholar
• Alturaiki W, Mubarak A, Al Jurayyan A, Hemida MG. The pivotal roles of the host immune response in the fine-tuning the infection and the development of the vaccines for SARS-CoV-2. Hum Vaccin Immunother. 2021;17(10):3297–3309. doi:10.1080/21645515.2021.1935172
   PubMed Web of Science ®Google Scholar
• Alosaimi B, Mubarak A, Hamed ME, et al. Complement anaphylatoxins and inflammatory cytokines as prognostic markers for COVID-19 severity and in-hospital mortality. Front Immunol. 2021;12:668725. doi:10.3389/fimmu.2021.668725
   PubMed Web of Science ®Google Scholar
• Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet. 2020;396(10262):1595–1606. doi:10.1016/S0140-6736(20)32137-1
   PubMed Web of Science ®Google Scholar
• Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature. 2020;583(7818):834–838. doi:10.1038/s41586-020-2342-5
   PubMed Web of Science ®Google Scholar
• Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631–637. doi:10.1002/path.1570
   PubMed Web of Science ®Google Scholar
• Farrag MA, Amer HM, Bhat R, et al. SARS-CoV-2: an overview of virus genetics, transmission, and immunopathogenesis. Int J Environ Res Public Health. 2021;18(12):6312. doi:10.3390/ijerph18126312
   Web of Science ®Google Scholar
• Ou XY, Liu Y, Lei XB, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11(1). doi:10.1038/s41467-020-15562-9
   Web of Science ®Google Scholar
• Walsh EE, Frenck RW, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450. doi:10.1056/NEJMoa2027906
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi:10.1056/NEJMoa2034577
   PubMed Web of Science ®Google Scholar
• Saadat S, Rikhtegaran Tehrani Z, Logue J, et al. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021;325(14):1467–1469. doi:10.1001/jama.2021.3341
   PubMed Web of Science ®Google Scholar
• Manisty C, Otter AD, Treibel TA, et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057–1058. doi:10.1016/S0140-6736(21)00501-8
   PubMed Web of Science ®Google Scholar
• Krammer F, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(14):1372–1374. doi:10.1056/NEJMc2101667
   PubMed Web of Science ®Google Scholar
• Bradley T, Grundberg E, Selvarangan R, et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med. 2021;384(20):1959–1961. doi:10.1056/NEJMc2102051
   PubMed Web of Science ®Google Scholar
• McDade TW, Schrock JM, D’Aquila R, et al. Symptoms of COVID-19 infection and magnitude of antibody response in a large community-based study. medRxiv. 2021. doi:10.1101/2021.02.04.21251170
   Google Scholar
• McDade TW, McNally EM, Zelikovich AS, et al. High seroprevalence for SARS-CoV-2 among household members of essential workers detected using a dried blood spot assay. PLoS One. 2020;15(8):e0237833. doi:10.1371/journal.pone.0237833
   Web of Science ®Google Scholar
• Schrock JM, Ryan DT, Saber R, et al. Cohabitation with a known Coronavirus disease 2019 case is associated with greater antibody concentration and symptom severity in a community-based sample of seropositive adults. Open Forum Infect Dis. 2021;8(7). doi:10.1093/ofid/ofab244
   Web of Science ®Google Scholar
• Legros V, Denolly S, Vogrig M, et al. A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity. Cell Mol Immunol. 2021;18(2):318–327. doi:10.1038/s41423-020-00588-2
   PubMed Web of Science ®Google Scholar
• Alkharaan H, Bayati S, Hellstrom C, et al. Persisting salivary IgG against SARS-CoV-2 at 9 months after mild COVID-19: a complementary approach to population surveys. J Infect Dis. 2021;224(3):407–414. doi:10.1093/infdis/jiab256
   Web of Science ®Google Scholar
• García-Montero C, Fraile-Martínez O, Bravo C, et al. An updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines. 2021;9(5). doi:10.3390/vaccines9050433
   Web of Science ®Google Scholar
• Yen JS, Wang IK, Yen TH. COVID-19 vaccination and dialysis patients: why the variable response. QJM. 2021;114(7):440–444. doi:10.1093/qjmed/hcab171
   Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586(7830):516–527. doi:10.1038/s41586-020-2798-3
   PubMed Web of Science ®Google Scholar
• Angyal A, Longet S, Moore SC, et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe. 2022;3(1):e21–e31. doi:10.1016/S2666-5247(21)00275-5
   PubMedGoogle Scholar
• Grzelak L, Velay A, Madec Y, et al. Sex differences in the evolution of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2. J Infect Dis. 2021;224(6):983–988. doi:10.1093/infdis/jiab127
   Web of Science ®Google Scholar
• Nomura Y, Sawahata M, Nakamura Y, et al. Age and smoking predict antibody titres at 3 months after the second dose of the BNT162b2 COVID-19 vaccine. Vaccines-Basel. 2021;9(9):1042.
   Web of Science ®Google Scholar
• Dan JM, Mateus J, Kato Y, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021;371(6529):eabf4063. doi:10.1126/science.abf4063
   PubMed Web of Science ®Google Scholar
• Faustini SE, Jossi SE, Perez-Toledo M, et al. Detection of antibodies to the SARS-CoV-2 spike glycoprotein in both serum and saliva enhances detection of infection. medRxiv. 2020. doi:10.1101/2020.06.16.20133025
   Google Scholar
• Sterlin D, Mathian A, Miyara M, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021;13:577. doi:10.1126/scitranslmed.abd2223
   Web of Science ®Google Scholar
• Cervia C, Nilsson J, Zurbuchen Y, et al. Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19. J Allerg Clin Immunol. 2021;147(2):545–557.e549. doi:10.1016/j.jaci.2020.10.040
   Web of Science ®Google Scholar
• Nomura Y, Sawahata M, Nakamura Y, et al. Attenuation of antibody titers from 3 to 6 months after the second dose of the BNT162b2 vaccine depends on sex, with age and smoking risk factors for lower antibody titers at 6 months. Vaccines. 2021;9(12):1500. doi:10.3390/vaccines9121500
   Web of Science ®Google Scholar
• Corman VM, Albarrak AM, Omrani AS, et al. Viral shedding and antibody response in 37 patients with middle east respiratory syndrome coronavirus infection. Clin Infect Dis. 2016;62(4):477–483. doi:10.1093/cid/civ951
   PubMed Web of Science ®Google Scholar
• Meyer B, Drosten C, Muller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175–183. doi:10.1016/j.virusres.2014.03.018
   PubMed Web of Science ®Google Scholar
• Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang PC. Chronological evolution of IgM, IgA, IgG and neutralisation antibodies after infection with SARS-associated coronavirus. Clin Microbiol Infect. 2004;10(12):1062–1066. doi:10.1111/j.1469-0691.2004.01009.x
   PubMed Web of Science ®Google Scholar
• Wu LP, Wang NC, Chang YH, et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg Infect Dis. 2007;13(10):1562–1564. doi:10.3201/eid1310.070576
   PubMed Web of Science ®Google Scholar
• Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251. doi:10.1038/s41467-020-16256-y
   PubMed Web of Science ®Google Scholar
• To KK, Tsang OT, Leung WS, et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect Dis. 2020;20(5):565–574. doi:10.1016/S1473-3099(20)30196-1
   PubMed Web of Science ®Google Scholar
• Guo L, Ren L, Yang S, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19). Clin Infect Dis. 2020;71(15):778–785. doi:10.1093/cid/ciaa310
   PubMed Web of Science ®Google Scholar
• Long QX, Liu BZ, Deng HJ, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020;26(6):845–848. doi:10.1038/s41591-020-0897-1
   PubMed Web of Science ®Google Scholar
• Jiang HW, Li Y, Zhang HN, et al. SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses. Nat Commun. 2020;11(1):3581. doi:10.1038/s41467-020-17488-8
   PubMed Web of Science ®Google Scholar
• Moscato G, Mazzetti P, Lucenteforte E, et al. Assessment of automated high-throughput serological assays for prediction of high-titer SARS-CoV-2 neutralizing antibody. J Clin Virology Plus. 2021;1(1):100016. doi:10.1016/j.jcvp.2021.100016
   Google Scholar
• Yoo JH. What we do know and do not yet know about COVID-19 vaccines as of the beginning of the year 2021. J Korean Med Sci. 2021;36(6):e54–e54. doi:10.3346/jkms.2021.36.e54
   PubMed Web of Science ®Google Scholar
• Yao L, Wang GL, Shen Y, et al. Persistence of antibody and cellular immune responses in coronavirus disease 2019 patients over nine months after infection. J Infect Dis. 2021;224(4):586–594. doi:10.1093/infdis/jiab255
   Web of Science ®Google Scholar
• Gallais F, Gantner P, Bruel T, et al. Anti-SARS-CoV-2 antibodies persist for up to 13 months and reduce risk of reinfection. medRxiv. 2021. doi:10.1101/2021.05.07.21256823
   Google Scholar
• Gaebler C, Wang Z, Lorenzi JCC, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021;591(7851):639–644. doi:10.1038/s41586-021-03207-w
   PubMed Web of Science ®Google Scholar
• Deming ME, Lyke KE. A ‘mix and match’ approach to SARS-CoV-2 vaccination. Nat Med. 2021;27(9):1510–1511. doi:10.1038/s41591-021-01463-x
   PubMed Web of Science ®Google Scholar
• Vogel G. Mixing Vaccines May Boost Immune Responses. American Association for the Advancement of Science; 2021.
   Google Scholar
• Lewis D. Mix-and-match COVID vaccines: the case is growing, but questions remain. Nature. 2021;595(7867):344–345. doi:10.1038/d41586-021-01805-2
   PubMed Web of Science ®Google Scholar
• Borobia AM, Carcas AJ, Pérez-Olmeda M, et al. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, Phase 2 trial. Lancet. 2021;398(10295):121–130. doi:10.1016/S0140-6736(21)01420-3
   PubMed Web of Science ®Google Scholar
• Hillus D, Schwarz T, Tober-Lau P, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1-nCoV19 and BNT162b2: a prospective cohort study. medRxiv. 2021. doi:10.1101/2021.05.19.21257334
   Google Scholar
• Schmidt T, Klemis V, Schub D, et al. Immunogenicity and reactogenicity of heterologous ChAdOx1 nCoV-19/mRNA vaccination. Nat Med. 2021;27(9):1530–1535. doi:10.1038/s41591-021-01464-w
   PubMed Web of Science ®Google Scholar
• Barros-Martins J, Hammerschmidt SI, Cossmann A, et al. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. Nat Med. 2021;27(9):1525–1529. doi:10.1038/s41591-021-01449-9
   PubMed Web of Science ®Google Scholar
• Kardani K, Bolhassani A, Shahbazi S. Prime-boost vaccine strategy against viral infections: mechanisms and benefits. Vaccine. 2016;34(4):413–423. doi:10.1016/j.vaccine.2015.11.062
   PubMed Web of Science ®Google Scholar
• Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines. 2021;9(8):910. doi:10.3390/vaccines9080910
   Web of Science ®Google Scholar